ClinicalTrials.gg

Program

culmerciclib

Also written as “TQB3616 capsules”, “TQB3616 capsule” and “TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen”.

In Sino Biopharmaceutical's pipeline, CDK2/4/6抑制剂. Its studies are mostly in Breast Neoplasms · Liposarcoma, led by Sino Biopharmaceutical.

Furthest: phase 3, since Apr 26, 202211 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical115 open or runningphase 3since Apr 26, 2022Feb 20, 2019Dec 2026phase 3 · NCT05780567
  • Named in Sino Biopharmaceutical’s own pipeline as TQB3616, phase 4, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 20, 2019First study: phase 1 study in Advanced Breast CancerFirst studyNCT03850873 · 40 enrolled · China
  2. Mar 11, 2021Phase 2 study in HR-positive, HER2-negative Advanced Breast CancerNCT04796623 · 122 enrolled · China
  3. Apr 1, 2022Phase 1 study in Breast NeoplasmsNCT05344729 · 16 enrolled · China
  4. Apr 26, 2022Phase 3 study in HR-positive, HER2-negative Breast NeoplasmsNCT05365178 · 432 enrolled · China
  5. May 11, 2022Phase 3 study in HR-positive,HER2-negative in Advanced Breast CancerNCT05375461 · 293 enrolled · China
  6. Aug 9, 2022Phase 2 study in LiposarcomaNCT05496569 · 26 enrolled · China
  7. Mar 10, 2023Phase 3 study in Breast NeoplasmsNCT05780567 · 1,946 enrolled · China
  8. Nov 21, 2023Phase 1 study in Breast NeoplasmsNCT06149611 · 8 planned · China
  9. Oct 28, 2024Phase 1 study in HealthyNCT06662773 · 40 planned · China
  10. Nov 20, 2024Phase 2 study in Breast NeoplasmsNCT06702618 · 33 enrolled · China
  11. Feb 22, 2025Phase 2 study in Breast NeoplasmsNCT06851442 · 8 enrolled · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Breast NeoplasmsNCT05780567

TargetBeta

“CDK2/4/6抑制剂”the company's pipeline, read by Claude · source
“An orally bioavailable, selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), ”NCIt, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
vustanaciclibregor-pharmaceuticals-incphase 23

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06851442Breast Neoplasms · China2TerminatedNov 20, 20258
NCT06702618Breast Neoplasms · China2Active, not recruitingJun 202633
NCT06662773Healthy · China1Not yet recruitingMar 202540
NCT06149611Breast Neoplasms · China1Not yet recruitingJun 20248
NCT05780567Breast Neoplasms · China3Active, not recruitingDec 20261,946
NCT05496569Liposarcoma · China2TerminatedJun 15, 202426
NCT05375461HR-positive,HER2-negative in Advanced Breast Cancer · China3CompletedJan 16, 2024293
NCT05365178HR-positive, HER2-negative Breast Neoplasms · China3Active, not recruitingJul 2, 2025432
NCT05344729Breast Neoplasms · China1CompletedAug 30, 202116
NCT04796623HR-positive, HER2-negative Advanced Breast Cancer · China2CompletedMay 24, 2024122
NCT03850873Advanced Breast Cancer · China1CompletedSep 23, 202140

How it is read

Names in the registry

  • “TQB3616 capsules”, 2 entries
  • “TQB3616 capsule”, 2 entries
  • “TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen”, 1 entry
  • “TQB3616”, 1 entry
  • “TQB3616 capsule+Fulvestrant Injection”, 1 entry

Codes read as this program: TQB3616.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.